Table 1.
Summary of Study 2 tumor (T) characteristics including age-at-diagnosis, MIP array estimate of HER2 gene copy number, HER2 protein overexpression level by ELISA, estrogen and progesterone receptor (ER, PR) status, tumor size, stage (T1–4), and nodal (N0–1) status
| Sample pair # | T # | Age | T HER2 CN (MIP) | T HER2 U/mg (ELISA) | T ER | T PR | T cm | Tumor stage | Nodal stage |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 21T | 50 | 12.2 | 659 | neg | neg | 3 | 2 | 0 |
| 2 | 22T | 57 | 7 | 372 | pos | pos | 1.7 | 1 | 0 |
| 3 | 23T | 39 | 7.8 | 362 | neg | neg | 2.5 | 2 | 1 |
| 4 | 24T | 38 | 3.8 | 359 | pos | neg | 2.7 | 2 | 0 |
| 5 | 25T | 47 | 5.5 | 429 | pos | neg | 3 | 4 | 1 |
| 6 | 26T | 53 | 17.5 | 420 | neg | neg | 2.4 | 2 | 0 |
| 7 | 27T | 78 | 18 | 282 | pos | pos | 3 | 2 | 1 |
| 8 | 28T | 79 | 4.5 | 838 | neg | neg | 2.5 | 2 | 0 |
| 9 | 29T | 46 | 25.8 | 430 | neg | neg | 3.5 | 2 | 1 |
| 10 | 30T | 39 | 29.9 | 326 | neg | neg | 2.5 | 2 | 1 |
| 11 | 31T | 54 | 5 | 608 | pos | neg | 4 | 2 | 1 |
| 12 | 32T | 54 | 14.1 | 493 | pos | pos | 1.8 | 1 | 0 |
| 13 | 33T | 55 | 18.1 | 481 | neg | neg | 2.5 | 2 | 0 |
| 14 | 34T | 54 | 56.7 | 814 | pos | pos | 5.5 | 3 | 1 |
| 15 | 35T | 77 | 12 | 446 | neg | neg | 6.2 | 4 | 1 |
| 16 | 36T | 68 | 9.8 | 627 | neg | neg | 2.4 | 2 | 0 |
| 17 | 37T | 52 | 18.1 | 697 | neg | neg | 3 | 2 | 0 |
| 18 | 38T | 52 | 3.6 | 401 | pos | neg | 3 | 2 | 0 |
| 19 | 39T | 65 | 4.7 | 447 | pos | neg | 2.2 | 2 | 0 |
| 20 | 40T | 67 | 3 | 434 | pos | neg | 6 | 3 | 0 |